Last reviewed · How we verify
NCT05917782
A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese Subjects
Phase 1 trial testing Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL) in Healthy Adult Subjects in 324 participants. Completed in 6 October 2023.
6 October 2023
Quick facts
| Lead sponsor | Connect Biopharm LLC |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 324 |
| Start date | 18 July 2023 |
| Primary completion | 6 October 2023 |
| Estimated completion | 6 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL) — full drug profile →
- Test drug (T2): CBP-201 injection (pre-filled syringe, 300 mg/2 mL) — full drug profile →
- Reference drug (R): CBP-201 injection (vial, 150 mg/1 mL) — full drug profile →
Conditions studied
- Healthy Adult Subjects — all drugs for Healthy Adult Subjects →
Sponsor
Connect Biopharm LLC — full company profile →
Who can join
Adults 18 to 45, any sex, with Healthy Adult Subjects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05917782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy Adult Subjects
Currently open trials in the same condition.
- NCT06635226 — Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects · Phase 1 · recruiting
Other Connect Biopharm LLC trials
Trials by the same sponsor.
- NCT05905133 — A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD · Phase 2 · unknown
- NCT05040113 — A Study On Human Mass Balance And Biotransformation · Phase 1 · completed
- NCT05017480 — A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China · Phase 2 · completed
- NCT04783389 — A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps · Phase 2 · terminated
- NCT04773678 — Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05917782 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Connect Biopharm LLC
- Last refreshed: 31 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05917782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing